lobbying_activities: 1558104

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1558104	6d1a8c28-a1b0-4317-9c6a-abb8f2e1155d	Q2	APOTEX CORP.	310973	APOTEX CORP.	2014	second_quarter	PHA	FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes;Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics; Federal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative, and; Federal policy relating to International Nonroprietary Names for Biosimilars	Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE		160000	0	0	2014-07-18T08:28:08.857000-04:00